In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
News|Articles|February 7, 2024
‘Vision Loss in Later Life is not Normal’: Vision Loss Projected to Rise in Older Adults
Author(s)Chelsie Derman, Connor Iapoce
Since the Baby Boomers are transitioning into older age by 2040 and 2050, the dramatic rise in the global aging population will increase demands for ophthalmic care.
Advertisement
Advertisement
As people approach 40, rods in the eyes begin weakening, tear ducts don’t work as well leading to dryer eyes, and lenses become more yellow or opaque. Inevitably, vision deterioration affects an individual’s daily lifestyle, from driving and working to reading and cooking. Worse,
Related to this article
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Advertisement
Advertisement